Disease variants alter transcription factor levels and methylation of their binding sites.
Marc Jan BonderRené LuijkDaria V ZhernakovaMatthijs MoedPatrick DeelenMartijn VermaatMaarten van ItersonFreerk van DijkMichiel van GalenJan BotRoderick C SliekerP Mila JhamaiMichael VerbiestEka H E D SuchimanMarijn VerkerkRuud van der BreggenJeroen van RooijNico LakenbergWibowo ArindrartoSzymon M KielbasaIris JonkersPeter van 't HofIrene NoorenMarian BeekmanJoris DeelenDiana van HeemstAlexandra ZhernakovaEttje F TigchelaarMorris A SwertzAlbert HofmanAndré G UitterlindenRené PoolJenny van DongenJouke J HottengaCoen D A StehouwerCarla J H van der KallenCasper G SchalkwijkLeonard H van den BergErik W van ZwetHailiang MeiYang LiMathieu LemireThomas J Hudsonnull nullP Eline SlagboomCisca WijmengaJan H VeldinkMarleen M J van GreevenbroekCornelia M van DuijnDorret I BoomsmaAaron IsaacsRick JansenJoyce B J van MeursPeter A C 't HoenLude H FrankeBastiaan T HeijmansPublished in: Nature genetics (2016)
Most disease-associated genetic variants are noncoding, making it challenging to design experiments to understand their functional consequences. Identification of expression quantitative trait loci (eQTLs) has been a powerful approach to infer the downstream effects of disease-associated variants, but most of these variants remain unexplained. The analysis of DNA methylation, a key component of the epigenome, offers highly complementary data on the regulatory potential of genomic regions. Here we show that disease-associated variants have widespread effects on DNA methylation in trans that likely reflect differential occupancy of trans binding sites by cis-regulated transcription factors. Using multiple omics data sets from 3,841 Dutch individuals, we identified 1,907 established trait-associated SNPs that affect the methylation levels of 10,141 different CpG sites in trans (false discovery rate (FDR) < 0.05). These included SNPs that affect both the expression of a nearby transcription factor (such as NFKB1, CTCF and NKX2-3) and methylation of its respective binding site across the genome. Trans methylation QTLs effectively expose the downstream effects of disease-associated variants.